For final drug product manufacturing, Actuate engaged two separate US-based partners. This parallel track strategy provided crucial redundancy during the COVID pandemic, ensuring that a shutdown or material shortage (e.g., glass vials) at one plant wouldn't derail their clinical programs.

Related Insights

The move toward a less efficient, more expensive global supply chain is not a failure but a strategic correction. Over-prioritizing efficiency created a dangerous dependency on China. Diversification, while costlier in the short term, is a fundamental principle of long-term risk management.

Hardware development is often stalled by supplier lead times. To combat this, proactively map out multiple, redundant manufacturing options for every component. By maintaining a constantly updated "lookup table" of suppliers, processes, and their current lead times, teams can parallelize workflows and minimize downtime.

By developing and owning the exact specifications for their fabrics—from the yarn to the finish—Faherty can move production between different manufacturers. This de-risks their supply chain from tariffs and geopolitical issues, as the "makers become less important."

Atomic Industries is scaling its manufacturing operations by creating a bifurcated factory system. Its first facility is dedicated solely to designing and creating molds. These molds are then shipped to a second, larger facility focused exclusively on high-volume part production, optimizing the workflow for both complex tooling and mass manufacturing.

By partnering with Fujifilm Cellular Dynamics (FCDI), the company that developed its core technology, Kenai avoids a costly and risky tech transfer process. FCDI's existing facility can handle both clinical and future commercial scale-up, a significant operational and financial advantage.

Unlike most biotechs that start with researchers, CRISPR prioritized hiring manufacturing and process development experts early. This 'backwards' approach was crucial for solving the challenge of scaling cell editing from lab to GMP, which they identified as a primary risk.

Actuate's CEO advises against out-licensing different indications of a single molecule to separate partners, calling it "splitting the baby." Because all programs rely on a single, shared safety database, one partner's negative safety event would impact all other programs, making the model unworkable.

Anticipating that independence from China will be a long-term, bipartisan US policy goal, Rivian intentionally designed its new R2 supply chain to be U.S.-centric. This strategic planning aims to align the business with persistent geopolitical trends, rather than just reacting to current tariffs.

When Shelter Skin's first shipment melted in transit, their vertically integrated model was a lifesaver. They could immediately change product seals and packaging. Had they outsourced to a lab, they would have been stuck with 10,000 faulty units and a potential $150,000 loss.

Despite US-China tensions threatening innovation, the likely outcome is 'coopetition'—a blend of competition and collaboration—as global pharmaceutical firms navigate the dual imperatives of advancing innovation and ensuring supply chain resilience.